Once-Daily, Controlled-Release Tramadol and Sustained-Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial
Autor: | Zoltan Harsanyi, William G. Bensen, André D. Beaulieu, Patricia Quigley, Paul M. Peloso, Glen T. D. Thomson, Boulos Haraoui, Andrew C. Darke, John Eisenhoffer, John Wade |
---|---|
Přispěvatelé: | University of Manitoba |
Jazyk: | angličtina |
Rok vydání: | 2008 |
Předmět: |
musculoskeletal diseases
lcsh:R5-920 business.industry Chronic pain Osteoarthritis medicine.disease Controlled release law.invention Clinical trial stomatognathic diseases Anesthesiology and Pain Medicine Diclofenac Neurology Randomized controlled trial law Anesthesia medicine Original Article Tramadol Once daily business lcsh:Medicine (General) medicine.drug |
Zdroj: | Pain Research and Management, Vol 13, Iss 2, Pp 103-110 (2008) |
ISSN: | 1203-6765 |
Popis: | OBJECTIVE: The present study was a randomized, parallel, double-blind comparison between controlled-release (CR) tramadol and sustained-release (SR) diclofenac in patients with chronic pain due to osteoarthritis of the hips and/or knees.METHODS: Patients with at least moderate pain intensity, and having received analgesics over the past three months, underwent a two-to seven-day washout of current analgesics before initiation of 200 mg CR tramadol or 75 mg SR diclofenac. During the eight-week study, patients returned to the clinic biweekly. CR tramadol doses were titrated to a maximum of 200 mg, 300 mg or 400 mg per day. SR diclofenac doses were titrated to 75 mg or 100 mg once daily, or 75 mg twice a day based on pain relief and the presence of side effects. For rescue analgesic, patients took acetaminophen as needed, up to 650 mg three times a day.RESULTS: Forty-five patients on CR tramadol and 52 patients on SR diclofenac were evaluable. Significant improvements from prestudy treatment were shown for visual analogue scale pain (P=0.0001), stiffness (PCONCLUSIONS: CR tramadol is as effective as SR diclofenac in the treatment of pain due to knee or hip osteoarthritis, with the potential for fewer of the serious side effects that characterize nonsteroidal anti-inflammatory drug administration. |
Databáze: | OpenAIRE |
Externí odkaz: |